E.g., 06/13/2021
E.g., 06/13/2021
Title Category Credit Event Date Price
PARP Inhibitors: Best Practices in Advanced Prostate Cancer Care in the Community Webcast (2021)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00
Prostate Cancer Update Webcast (2020)
    • 1.50 AMA PRA Category 1 Credit™
    • 1.50 Non-Physician Participation
$0.00 This course will offer a review of what faculty believe are the most important articles in the English-speaking literature on prostate cancer from May 2018 to May 2019. Focus will be placed on articles that have relevance to clinical practice, including both research and clinical articles.ACKNOWLEDGEMENTSSupport provided by independent educational grants from:AstellasAstraZenecaBristol-Myers SquibbGenentechMerckPfizer, Inc.Sanofi Genzyme
Renal Cell Carcinoma: Surgical & Medical Management of High-Risk Renal Cell Carcinoma: New Paradigms for Treatment Webcast (2020)
    • 1.50 AMA PRA Category 1 Credit™
    • 1.50 Non-Physician Participation
$0.00 Treatment of renal cell carcinoma has changed with expanding indications for Robotic Partial nephrectomy and inclusion of new FDA approved treatments for advanced RCC. This course will focus on didactic case discussions using video tape analysis of surgical treatment, setup and successful completion of Robotic Partial nephrectomy, complication management and how to optimize outcomes. Urologists are now faced with treatment of advanced RCC with a host of options, from tyrosine kinase inhibitors to checkpoint inhibitors.
Robotic Urologic Surgery: A Technical Masterclass Webcast (2018) $689.00 Robotic Urologic Surgery: A Technical Masterclass provides a structured approach to advanced robotic surgery for conditions of the prostate, kidney, and bladder with an emphasis on radical prostatectomy and partial nephrectomy. This course will also focus on emerging technologies including genomic testing and advanced imaging. Experienced world-class faculty with more than a decade of experience with complex robotic surgery will provide you with instruction to refine your technique and achieve superior results.
Self-Assessment Study Program SASP (2019) $295.00 The SASP is the AUA’s most popular study tool for exam preparation! For over 40 years, the AUA's Self-Assessment Study Program (SASP) has been a leading educational resource for urologists-in-training and practicing urologists.
Self-Assessment Study Program SASP (2020) $306.00 The SASP is the AUA’s most popular study tool for exam preparation!For over 40 years, the AUA's Self-Assessment Study Program (SASP) has been a leading educational resource for urologists-in-training and practicing urologists. Developed each year, the SASP is a 150-question, multiple-choice practice examination that addresses the core curriculum of medical knowledge and latest advances in patient care. The SASP may be taken open or closed book, and provides correct answers with detailed answer rationales, and scientific references.
Self-Assessment Study Program SASP (2021) $310.00 The SASP is the AUA’s most popular study tool for exam preparation!For over 40 years, the AUA's Self-Assessment Study Program (SASP) has been a leading educational resource for urologists-in-training and practicing urologists.
Sequencing of Agents and Combination of Treatment for Metastatic RCC Podcast (2020)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Sequencing of Agents and Combination of Treatment Options for Bladder Cancer Podcast (2020)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Targeted Therapies and Integration with Surgical Management of RCC Podcast (2020)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
The Changing Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion Webcast (2020)
    • 3.00 AMA PRA Category 1 Credit™
    • 3.00 Non-Physician Participation
$0.00 As a direct result of the significant increase in multiple FDA-approved therapeutic agents for use in patients with advanced prostate cancer, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex.
The Expanding Role of Immune Checkpoint Inhibitors in MIBC and NMIBC Podcast (2020)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Trimodality Therapy for Management of Muscle Invasive Bladder Cancer Webcast (2020)
    • 1.50 AMA PRA Category 1 Credit™
    • 1.50 Non-Physician Participation
$0.00 This course is a comprehensive review of tri-modal therapy for muscularis propria invasive urothelial carcinoma of the bladder with a multidisciplinary faculty including urology, radiation oncology, and medical oncology. We will review results from prospective randomized trials and large institutional experiences in tri-modality bladder sparing therapy. The course will focus on the Urologist’s critical role in patient selection for this approach vs.
Trimodality Therapy for Management of Muscle Invasive Bladder Cancer Webcast (2021)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 This course is a comprehensive review of tri-modal therapy for muscularis propria invasive urothelial carcinoma of the bladder with a multidisciplinary faculty including urology, radiation oncology, and medical oncology. We will review results from prospective randomized trials and large institutional experiences in tri-modality bladder sparing therapy. The course will focus on the Urologist's critical role in patient selection for this approach vs. radical cystectomy.
Update Series (2015) Lesson 10: Clinical Stage I Testicular Cancer $0.00 For the most timely topics and latest surgical techniques in urology, you won’t want to miss the 2015 AUA Update Series—the AUA’s most popular self-study CME product.All new topics for 2015!

Pages